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CObjectives: Randomized clinical trials frequently attract volunteer pa-
tients who were either non-compliant or seeking to switch therapies.
Patients on active therapies often undergo a washout period after
which a single medication is initiated. Observational research has the
potential to compare alternative treatments under a wider range of
clinical situations if care is taken to document each patient’s treatment
history. Methods: This study used paid claims data from a large com-
mercial insurer to investigate drug therapy outcomes in schizophrenia.
Episodes of drug therapy were defined each time a patient initiated or
restarted drug therapy using an antipsychotic, antidepressant or mood
stabilizing medication. Episode definitions were based on calculations
of continuous drug therapy using a 15-day gap definition. A total of
21,570 episodes of drug therapy were included in the analysis, some of
which used two drugs as initial therapy. Results: Most episodes were
initiated using a mood stabilizing drug (27%) or an antidepressant O
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doi:10.1016/j.jval.2011.02.00238%). Over 62% of all episodes were augmentation therapy in which a
sychotropic drug was added to an existing psychotropic medication,
ollowed by switching episodes (22%) and restart episodes (16%). Pa-
ient outcomes measured by either duration of uninterrupted therapy
r one-year post-treatment cost varied significantly with patient treat-
ent history, especially episode type. The comparative effectiveness
f alternative therapies is sensitive to the extent to which treatment
istory is taken into account. Conclusions: Observational comparative
ffectiveness research should capture and evaluate patient outcomes
cross a wide range of patients taking into account the patient’s treat-
ent history.
eywords: comparative effectiveness research, schizophrenia, treat-
ent history.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Research using retrospective data base analyses can significantly
improve our understanding of the comparative, real-world effec-
tiveness of alternative therapies. In particular, real world data in-
clude patients that span the full range of disease severity, co-mor-
bidity profiles and treatment history who are typically excluded
from well controlled, prospective clinical trials. Observational re-
search, however, also has significant limitations. Real-world pa-
tients are not randomly assigned to treatment which creates sig-
nificant heterogeneity across alternative treatments. To reduce
heterogeneity, many retrospective data base studies mimic clini-
cal trials and focus on a narrow sub-population for study. Many of
the inclusion and exclusion criteria use in these studies are based
on treatment history. For example, researchers often limit retro-
spective comparative effectiveness studies to patients who have
not used study medications for significant periods of time. These
extended “washout” periods are particularly restrictive when
studying chronic illnesses, such as severe mental illness, for
which achieving effective long-term drug therapy is difficult and
an individual patient may have initiated multiple attempts at drug
therapy during a multiple-year data period.
There are alternatives for improving the internal validity of
retrospective data base analyses without artificially narrowing the
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Policy, 1540 E. Alcazar St., Rm. CHP 140, Los Angeles, CA 90089-900
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1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.range of patients to be studied. Specifically, the potential bias cre-
ated by heterogeneity across alternative treatment groups can be
mitigated by creating a more complete set of independent vari-
ables that are correlated to treatment selection and patient out-
comes. While paid claims data have some important limitations in
this regard, such as missing clinical data, claims data are well
suited for documenting the medical history of the patient prior to
treatment, including diagnosis, prior use of health services and
the patient’s drug treatment history using the medications under
study. Moreover, including all patient episodes regardless of the
drug use history at the time of treatment initiation allows the
research to investigate comparative effectiveness across the full
range of patients treated under real-world clinical conditions.
The patient’s drug treatment history may be particularly im-
portant for patients with severe mental illnesses. Two recently
published studies by Chen, McCombs, and Park [1,2] have reported
hat medication compliance and the cost of treating patients with
chizophrenia in the California Medicaid Program (MediCal) varied
ignificantly with the patient’s treatment history. Specifically, pa-
ients switching medications or augmenting an existing treatment
egimen displayed significantly longer time to all-cause discontin-
ation (TTAD) and the highest post-treatment cost over 1 year
hen compared with patients restarting a therapy used previ-
usly. Other treatment history variables were also significant pre-
artment of Clinical Pharmacy and Pharmaceutical Economics and
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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680 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 7 9 – 6 8 6dictors of patient outcomes. For example, patients initiating com-
bination therapy and duration of therapy on the previous episode
were positively correlated with TTAD, whereas the number of
treatment attempts in the year prior to starting a new episode was
negatively correlated with TTAD.
Chen, McCombs, and Park [1,2] also documented that the com-
arative effectiveness comparisons of atypical antipsychotics to con-
entional medications were sensitive to patient treatment history.
he atypical antipsychotics were associated with reductions in the
ost of medical services that partially offset the higher cost of these
edications with the exception of patients switching therapy with-
ut a break in treatment. The study also found that patients using
typical antipsychotics achieved longer TTAD relative to patients us-
ng typical antipsychotics (TAP). These latter results were consistent
ith previous, more restrictive studies using either retrospective
aid claims data [3–5] or data from prospective trials designed to
ore closely approximate real-world clinical practice [6,7].
The importance of treatment history in determining patient
utcomes and the differences in treatment history across alterna-
ive drugs raises concerns about bias in retrospective database
tudies that do not explicitly control for treatment history. Mar-
hall and McCombs [8] investigated this issue using the MediCal
ata for patients with schizophrenia. This study demonstrated
hat comparisons of TTAD were sensitive to the exclusion of pa-
ient treatment history. However, the atypical antipsychotics con-
istently dominated conventional medications with regard to patient
ompliance while there were small changes in the comparisons be-
ween the newer medications.
This research used paid claims data from a large commercial
nsurer in the United States to investigate the impact of patient
reatment history on a wide range of patient outcome measures
or patients with schizophrenia. First, the differences in treatment
istory across alternative medications are documented. Next, the
nalyses estimates impact of treatment history on TTAD and costs
ver the first post-treatment year by type of service. Finally, esti-
ates of head-to-head comparative effectiveness analyses across
lternative therapies are compared using model specifications
ith and without treatment history variables.
Methods
Data
This research used paid claims data from a large commercial in-
surer in the United States that offered a wide range of insurance
products (commercial, Medicare, Medicaid), plan designs (HMO,
point of service, PPO, exclusive provider organizations, indemnity
plans), and drug formulary structures to members across the
United States. The data period was June 2003 to May 2006 and
included both medical and prescription drug claims. Patients with
schizophrenia were identified based upon finding an ICD-9 diag-
nosis code for schizophrenia (295.xx) recorded in their paid claims
history. The unit of analysis is the treatment episode, which is
broadly defined to include all available drug therapy attempts ini-
tiated by patients during the data period using antipsychotics,
mood stabilizers or antidepressants. Four types of episodes were
defined initially based on whether or not the patient was on active
therapy when a new treatment attempt was initiated and whether
or not the patient was changing therapies.
Definition of continuous therapy
A key element in this research is the definition of continuous drug
therapy which was used to differentiate between treatment epi-
sode types. Duration of therapy was defined as a continuous use of
a medication up to a gap of greater than 15 days between the end
of estimated days-of-supply and the next prescription refill. Theestimated days of supply was set equal to the sum of the reported
days supply on the prescription claim and a running count of “un-
used” days of supply that a patient may have on hand due to the
early refill of previous prescriptions. The sum of unused days of sup-
ply was capped at 30 days. TTAD was calculated for each individual
medication and across all psychotropic medications used by the pa-
tient so long as no gap in drug therapy greater than 15 days appeared
as patients switched therapies. The 15-day gap is consistent with
findings by Weiden et al. [9] that the risk of hospitalization increased
significantly in patients with schizophrenia after breaks in therapy as
short as 10 days. Patients may have multiple episodes on one medi-
cation and/or across multiple medications.
Unit of observation
The unit of observation for the analyses was the drug treatment
episode. Four types of treatment episodes were defined based on
two elements derived from the patient’s treatment history at the
time a new treatment attempt was initiated: 1) whether or not the
patient was changing medications, and 2) whether or not the pa-
tient was on active therapy. Both elements of treatment history
were based on the medications used in patient’s most recent prior
episode and the duration of uninterrupted therapy achieved based
on a 15-day gap in drug availability.
First observed episode
By definition, each patient has one “first” episode of psychotropic
drug therapy recorded in the available data set. Many of these first
episodes appear at the beginning of the data period and include
multiple drugs making it likely that these are continuing episodes
initiated in the time period prior to the data period. Nevertheless,
even using multiple years of data and screening episodes for pe-
riod of data prior to the episode start date, it is impossible to de-
termine whether or not the first observed episode for a patient is
truly the first time a patient used a psychotropic medication.
Therefore, the initial treatment episode observed for each patient
was excluded from further analysis.
Restart episodes using the same medication
Restart episodes were defined when the patient was not on active
drug therapy and initiated therapy with the medication used in
their most recent prior treatment attempt.
Switching episodes
A switching episode was defined when a patient changed medica-
tion. If the patient was on active therapy at the time a new psy-
chotropic medication was initiated, all previous medications had
to be discontinued within 60 days.
Augmentation episodes
An augmentation episode was defined when a patient added a
“new” therapy without a break in therapy and continued to pur-
chase one or more of their previous psychotropic medications be-
yond 60 days.
Other elements of treatment history
Several additional variables were created from the data that reflect
on the patient’s treatment history at the time that a new episode
of therapy was initiated. These variables were used as indepen-
dent variables in the analyses of TTAD and post-treatment cost.
Patients initiating therapy using two or more new medications
were defined as initiating combination therapy. The mix of psy-
chotropic drugs used in the prior 6 months was also documented
as dichotomous variables, including the use of depot formulations
as a separate category using data from all previous treatment at-
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681V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 7 9 – 6 8 6tempts. Finally, a count of prior treatment episodes initiated in the
prior 6 months was abstracted from the data.
Inclusion and exclusion criteria
Once all of the episodes of care included in the available data were
created, the following inclusion and exclusion criteria were then
applied to each episode:
1. Patient episodes must include a minimum of 180 days of patient
eligibility prior to the date the treatment episode was initiated.
. Patient episodes must include a minimum of 360 days (12
months) of data following the initiation of treatment.
. Patients were at least 10 years of age at the time treatment was
initiated.
. Patient episodes with more than $500,000 (USD) in total cost
prior to or following the initiation of therapy were excluded
(0.14% of all schizophrenia and bipolar patients).
. Patient episodes with negative cost prior to or following the
initiation of treatment were excluded. Negative cost values
were generated if the patient’s paid claim file included an ad-
justment claim correcting for prior overpayments due to prob-
lems such as duplicate claims.
. Patients with a history of nursing home use or hospice care
were excluded from the analysis.
. The first observed episode of treatment for each patient was
excluded due to the ambiguity concerning the patient’s drug
treatment history.
Patient outcome measures
The patient outcome measures for this research project are bro-
ken down into two categories, each of which includes multiple
outcome measures. Drug therapy outcome measures include days
of uninterrupted drug therapy on the initial drug and on all psy-
chotropic drugs so long as changes in therapy are accomplished
without a break in therapy, and time to a change in medications
(switch or augmentation). Health-care cost variables were mea-
sured by summing the amount charged on the paid claim during
the first post-treatment year broken down by type of service and
time to hospitalization. The amount charged includes any deduct-
ible or copayment obligations of the patient, but may overstate the
payment from the insurance company that did not make allowed
charge data available.
Independent variables
The development of an exhaustive list of independent variables for
inclusion in the multivariate statistical models is the first line of de-
fense against treatment selection bias in non-randomized studies
that compare patient outcomes and costs across alternative treat-
ment options. This study developed independent variables related to
patient demographics, medical and mental health diagnostic profiles
of the patient, and prior use of health-care services by type of service.
Information related to the patient’s prior use of antipsychotic medi-
cations included 1) a dichotomous variable indicating that two or
more medications were used as initial therapy; 2) a set of dichoto-
mous variables indicating the types of medications used in the prior
6-month period (typical antipsychotics, atypical antipsychotics,
mood stabilizers, antidepressants, and depot formulations); 3) the
number of psychotropic drug treatment episodes initiated in the
prior 6 months; and 4) the number of days between episodes (in-
cluded in the analysis of restart episodes only).
Statistical methods
The statistical approach that was used varied depending on the
outcome measure being analyzed. Ordinary least squares (OLS)
regression models were estimated for continuous outcome vari-ables; Cox proportional hazard models were estimated for time-
to-event outcome measures and logistic regression models were
estimated for dichotomous outcome variables. Adjustments in the
OLS estimated standard errors for multiple observations (epi-
sodes) per patient were applied using methods developed by
White [10]. Other statistical methods, such as patient fixed-effects
models, could not be used as an estimation strategy due to the
methods used to create units of observation covering all treatment
attempts by the patient. This focus on accuracy and completeness
of the episode definition process resulted in overlapping episodes
of unequal length. This data structure does not fit in the typical
repeated measures framework on which fixed-effects and other
methods are designed to work. Most researchers have overcome
these challenges by limiting the range of episodes included in their
research, which would defeat the purpose of this research.
Results
Baseline descriptive statistics
The descriptive statistics for episodes of treatment initiated by
patients with a diagnosis of schizophrenia are displayed in Table
1. The study population of 5,909 patients initiated a total of 21,570
patient episodes, which met the inclusion and exclusion criteria
for this study. The first observed episode for each of the 5,909
patients was excluded.
Several results are of interest. Patients were defined as having
schizophrenia if they received a diagnosis of schizophrenia at any
time in the data period. The data on the initial drug used in these
episodes suggest that several of these patients may have been
treated for possible bipolar disorders. Specifically, mood stabiliz-
ers and antidepressants make up approximately 27% and 38% of
the drug therapy episodes initiated by these patients with a
schizophrenia diagnosis. The use of nonantipsychotic medica-
tions is most pronounced in episodes in which two or more drugs
are filled on the index date for the episode (combination therapy)
with 54% and 64% of all combination episodes including these
medications, respectively.
There are significant differences in the characteristics of pa-
tients by episode type. Patients initiating switching episodes tend
to be younger than patients restarting or augmenting therapy; pa-
tients restarting therapy using the same medication are more
likely to be greater than 65 years old when compared with patients
augmenting or switching therapies. Patients restarting therapy
also use risperidone and typical antipsychotics more frequently
than in other episode types, have fewer prior episodes of treat-
ment using a psychotropic drug, and cost about half as much as
patients initiating an augmentation or switching episode in the 6
months prior to treatment initiation.
Combination episodes are much more likely to include risperi-
done (23%), quetiapine (18.7%), aripiprazole (14.2%), or conven-
tional antipsychotics than olanzapine (3.4%), and ziprasidone ep-
isodes fall somewhere in the middle (9.7%). As noted before, the
use of mood stabilizers and antidepressants is particularly high in
combination episodes (54% and 64%, respectively).
Descriptive statistics for patient outcomes
Table 2 provides descriptive statistics for patient outcomes by ep-
isode type, and by combination versus monotherapy. Persistence
with drug therapy differs significantly by episode type. Patients
restarting a previous drug therapy exhibit significantly shorter
TTAD whether measured for the initial drug (128 days vs. 183 for
switch episodes and 197 for augmentation episode) or for all re-
lated psychotropic medications (172 days vs. 299 and 486 for
switching and augmentation, respectively). Not surprisingly, pa-
tients initiating a restarting episode also had the lowest rate of 1
682 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 7 9 – 6 8 6year persistence on their initial drug (10%) or on all related psy-
chotropic drugs (17.2%), and they had the lowest switch rates of all
three episode types. Equally important, patients restarting their
previous therapy also exhibited the lowest cost in the 1-year post-
treatment period.
Differences in patient outcomes are much less pronounced
when comparing monotherapy episodes with combination ther-
apy. Probably the most significant difference in patient outcomes
are that patients initiating with two or more drugs were more
likely to be hospitalized in the first post-treatment year (42.2% vs.
34%) and experienced higher costs ($12,806 vs. $9,413 [USD]) rela-
tive to patients initiating treatment on monotherapy.
Multivariate results
The OLS models for the impact of treatment history on the patient
outcomes achieved by patients with schizophrenia are presented
in Table 3 and the logistic and Cox models are presented in Table
4. Augmentation episodes and combination therapy are the com-
Table 1 – Baseline characteristics for patients with schizop
therapy: N = 21,570.
Episod
Switch Resta
N  4,633 N  3,
Mean age (in years) [SD] 39.9 [15.7] 43.5 [1
Age category (%)
10–18 years old 8.3 3.8
18–25 years old 13.6 11.3
25–35 years old 14.6 12.2
35–45 years old 23.1 24.0
45–55 years old 23.7 25.9
55–65 years old 10.6 13.7
65 years old 6.1 9.0
Male (%) 37.1 40.9
Initial drug number (%)
Olanzapine 2.9 3.1
Risperidone 9.9 19.5
Quetiapine 9.3 9.1
Ziprasidone 5.3 4.4
Aripiprazole 10.9 8.2
Typical antipsychotics 5.9 18.0
Mood stabilizer 27.6 25.9
Antidepressant 37.3 36.7
Prior episode/year 1.63 [1.45] 1.00 [0
Schizophrenia Dx (prior 6 months) (%)
Acute 2.4 1.7
Simple 1.3 1.5
Catatonic 0.7 0.3
Disorganized 0.5 0.8
Latent 0.5 0.9
Paranoid 14.3 21.6
Residual 1.7 3.5
Schizo-affective 27.4 29.0
Not otherwise specified 13.1 13.9
Prior use ($/6 months)
Ambulatory care 6,919 [11,209] 4,471 [9
Prescription drugs 2,791 [2,702] 2,130 [2
AP drug cost 1,144 [1,370] 937 [1
Acute hospital care (%) 40.3% 19.1%
Acute hospital care 9,271 [21,381] 3,857 [1
Costs net of Rx 17,334 [28,305] 9,265 [1
TOTAL COST 20,125 [29,132] 11,395 [2
AP, antipsychotic; Dx, diagnosis; Rx, prescription.parison groups. Only the results for the treatment history vari-ables are presented due to space limitations. Results from the full
models are available from the corresponding author.
Impact of episode type on patient outcomes
Episode type has a significant and large impact on measures of
patient drug therapy compliance when compared to episodes of
augmentation therapy. Patients restarting therapy using a drug
used in their most recent prior treatment attempt terminate their
initial therapy nearly 83 days sooner than patients initiating an
augmentation episode. When measured over all related psycho-
tropic medications, this difference increases to 273 days in a sam-
ple of patients required to only have a minimum of 360 days of
data. Results for switching episodes are similar but less dramatic:
22 fewer days of therapy on the initial medication used in the
switching episode and 155 fewer days of continuous therapy mea-
sured across all relevant drugs. A shorter duration of therapy in
restart and switching episodes, however, does not result in higher
costs. Patients restarting or switching therapy are consistently
ia by episode type and number of drugs used as initial
e Number of initial drugs
Augmentation Monotherapy Combination therapy
N  13,451 N  19,216 2,354
41.8 [15.4] 41.9 [15.6] 39.5 [14.6]
6.6 6.5 6.8
10.8 11.2 14.4
13.4 13.4 14.1
24.3 23.8 25.4
25.5 25.2 25.0
12.8 12.8 9.9
6.6 7.2 4.5
35.0 36.1 38.9
2.2 2.4 3.4
8.4 9.0 23.0
9.8 8.5 18.7
4.4 4.0 9.7
7.0 7.3 14.2
6.2 7.5 12.7
28.7 24.8 54.0
39.4 35.4 63.9
2.48 [1.94] 2.15 [1.80] 1.28 [1.65]
1.5 1.7 1.9
1.0 1.2 0.4
0.3 0.4 0.3
0.6 0.6 0.3
0.5 0.6 0.6
12.0 14.3 11.9
1.7 2.1 1.6
32.9 31.2 29.7
13.5 13.7 11.9
7,325 [11,794] 6,717 [11,478] 7,260 [10,736]
4,115 [3,271] 3,544 [3,121] 3,233 [2,821]
1,720 [1,811] 1,480 [1,685] 1,383 [1,511]
35.5% 32.2% 48.0%
7,969 [19,560] 7,100 [18,623] 11,535 [23,704]
17,014 [26,710] 15,298 [25,656] 20,177 [30,051]
21,129 [27,601] 18,841 [26,586] 23,410 [30,723]hren
e typ
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683V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 7 9 – 6 8 6$4441 [USD], respectively, P  0.0001 for both estimates). The
lower cost in restart and switching episodes is consistent across all
type of services except for acute hospital care, which is signifi-
cantly higher for patients who restart therapy ($1684 [USD], P 
0.0001).
In general, the OLS results in Table 3 are confirmed by the
ogistic and proportional hazard analyses of events reported in
able 4. Patients initiating a restart or switching episode are less
ikely to complete one year of uninterrupted drug therapy and
ore likely to discontinue therapy than patients initiating an aug-
entation episode. Patients initiating a switching episode, how-
ver, are significantly more likely to switch again within 1 year
han patients augmenting a pre-existing therapy (odds ratio 
.56; hazard ratio  1.41, P  0.0001 for both estimates). Patients
estarting therapy are less likely to be admitted to an acute hospi-
al than patients initiating an augmentation episode (odds ratio
.74; hazard ratio 0.76, P 0.0001), yet their cost for hospital care
as found to be significantly higher than patients augmenting
herapy (Table 3).
Table 2 – Drug therapy outcomes and post-treatment healt
and number of drugs used as initial therapy: N = 21,570.
Episod
Switch Resta
N  4,633 N  3,
Duration of therapy (TTAD)
Initial therapy 183 [196] 128 [1
All related drugs 299 [269] 172 [2
Completed 360 days of therapy (%)
Initial therapy 16.2% 10.0%
All related therapy 34.5% 17.2%
Switched/augment within 1 year (%) 53.2% 28.1%
Post-treatment costs (1 year) ($)
Ambulatory care 10,887 [20,297] 7,910 [1
Prescription drugs 4,969 [5,158] 3,802 [3
AP drug cost 2,147 [2,662] 1,766 [2
Hospital admission within 1 year (%) 35.7% 23.9%
Acute hospital costs 10,002 [25,652] 5,865 [1
Costs net of Rx 23,035 [39,496] 15,542 [3
TOTAL COST 28,004 [41,261] 19,344 [3
AP, antipsychotic; Rx, prescription; TTAD, time to all-cause discontin
Table 3 – Estimates of patient history variables on days of
schizophrenia: all treatment episodes: N = 21,570.
Drug treatment history Duration on
initial AP
Duration on
all drugs
Ambulator
costs
R2  0.0544 R2  0.2115 R2  0.2146
Episode type (vs. augmentation)
Restart 82.9* 273.0* 1597*
Switch 21.6* 154.9* 818†
Monotherapy (vs. combination
therapy)
30.3* 12.3 501
Prior drug use (6 months)
Typical antipsychotics 19.3* 13.4† 1223‡
Atypical antipsychotics 24.4* 34.6* 2220*
Antidepressants 41.6* 46.7* 888‡
Mood stabilizers 31.6* 2.4 1079*
Depot AP prior 37.0 31.3 7913†
Number of prior episodes 5.74* 30.29* 138.74*
AP, antipsychotic; Rx, prescription.
* P  0.0001; † P  0.05; ‡ P  0.01.Other treatment history factors
The impact of monotherapy relative to combination therapy dis-
plays a pattern similar to the impact of episode type. Monotherapy
is associated with shorter duration of therapy and lower post-
treatment costs with the exception of significantly higher acute
hospital costs. Conversely, the number of treatment attempts in
the prior 6 months is positively correlated with duration of ther-
apy and with higher costs across all types of service. Finally, the
mix of drugs used in the prior 6 months has a mixed but significant
impact of patient outcomes. Patients with a history of using an
antipsychotic medication in the prior 6 months are consistently
less compliant and less costly to treat in the first post-treatment
year. Patients with a history of antidepressant use are also less
compliant but the impact of prior antidepressant use on post-
treatment cost is mixed. Patients with schizophrenia with a his-
tory of mood stabilizer use within 6 months of initiating an epi-
sode of therapy are less compliant and more costly to treat.
The pattern of estimated effects for monotherapy, prior drug
used, depot therapy, and number of episodes of drug therapy
re cost for patients with schizophrenia by episode type
e Number of initial drugs
Augmentation Monotherapy Combination therapy
N  13,451 N  19,216 2,354
197 [214] 178 [203] 224 [219]
486 [296] 399 [307] 362 [293]
18.3% 15.8% 22.2%
63.3% 50.2% 45.2%
44.4% 42.7% 51.2%
] 12,767 [20,196] 11,503 [19,777] 12,195 [20,878]
7,842 [6,183] 6,601 [5,905] 6,334 [5,751]
3,343 [3,442] 2,832 [3,208] 2,826 [3,202]
37.4% 34.0% 42.2%
] 10,723 [26,599] 9,413 [24,521] 12,806 [30,905]
] 26,833 [39,892] 23,748 [37,839] 27,827 [44,794]
] 34,675 [41,892] 30,348 [39,954] 34,161 [46,217]
n.
py and post-treatment costs: patients with
rug costs
(all Rx)
Antipsychotic
drug cost
Hospital costs
R2  0.1090
Net costs
R2  0.1978
Total costs
R2  0.2182
2  0.2218 R2  0.1516
2722* 1183* 1684* 4463* 7186*
2137* 994* 492 2304‡ 4441*
295 347* 2039† 1885 2180
736* 121 109 1453 2189‡
429* 1061* 1716* 2875* 2447*
228‡ 413* 350 826 597
769* 71 794† 1802‡ 2572
1616‡ 1872* 6000 15784‡ 17401*
279.68* 111.25* 198.80* 448.79* 728.47*h-ca
e typ
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684 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 7 9 – 6 8 6(Table 3) were generally confirmed by the logistic and proportional
hazard model results found in Table 4. Patients with a history of
atypical antipsychotic drug use are less likely to switch medica-
tions and are less likely to be admitted to the hospital in the post-
treatment period. Conversely, patients with a history of mood sta-
bilizer use are more likely to switch and are more likely to be
admitted to an acute hospital.
Comparative effectiveness comparisons
Impact of treatment history
This research found that a patient’s drug treatment history has
a significant and clinically important impact on patient out-
comes (Tables 3 and 4). Moreover, treatment history also varies
significantly across alternative medications (Table 1). Taken to-
gether, these results suggest that head-to-head comparisons
across alternative drugs could be significantly biased if these
analyses do not take treatment history into account, which is
common in most retrospective database comparisons of drug
performance [3– 6].
The extent of possible bias in comparisons across the alterna-
tive drugs in the treatment of patients with schizophrenia is pre-
sented in Table 5. The “no history” model parallels “usual practice”
nd includes only a set of dichotomous variables for the specific
rug used as initial therapy (typical antipsychotics [TAP] as the
omparison group). The model with treatment history includes
ariables for episode type (in the all episodes analysis), mono-
herapy, mix of prior drugs, and number of episodes in the prior 6
onths.
All episodes
Standard estimation models for TTAD patient outcomes that do
not include variables related to patient treatment history favor the
atypical antipsychotics relative to TAP – between 11 days for ris-
peridone and 61 days for ziprasidone. These results also hold for
comparisons of mood stabilizers (45 days) and antidepressants
(26 days) as initial therapy relative to TAP. The gaps in TTAD
favoring the atypical antipsychotics relative to TAP are signifi-
cantly reduced when treatment history variables are added to the
Table 4 – Estimates of patient history variables on event ou
N = 21,570 (5,909 patients).
Independent variables Logistic regression mo
(Odds ratios vs. TAP
Duration on
initial 360
days
Duration on
all 360
days
Switched
augmen
w/i 1 yea
Pseudo
R20.0393
Pseudo
R20.1244
Pseudo
R20.038
Episode type (vs. augment)
Restart 0.46† 0.16† 0.77†
Switch 0.78† 0.34† 1.56†
Mono-therapy (vs.
combination therapy)
0.74† 0.88 0.79‡
Prior rx use (6 mos.)
Typical antipsychotics 0.88 1.01 0.95
Atypical antipsychotics 0.83† 0.95 0.89‡
Antidepressants 0.69† 0.82† 1.05
Mood stabilizers 0.81† 1.15‡ 1.17†
Depot AP prior 1.18 1.48 0.95
Number of prior episodes 1.02 1.073† 1.080†
* P  0.05; † P  0.0001; ‡ P  0.01.analysis and, in the case of olanzapine and risperidone, favorableTTAD effects disappear entirely. Conversely, the estimated im-
pacts of the atypical antipsychotics on health-care costs relative to
TAP improve when the independent variables for patient treat-
ment history are included in the analysis. For example, in the
model with no treatment history, quetiapine was estimated to
increase total cost by $4022 (USD; P  0.0001). This estimate
dropped to greater than $3135 (USD; P 0.01) when the drug treat-
ment variables are included in the analysis.
By episode type
One way to take patient treatment history into account is to conduct
separate analyses by episode type. These analyses are reported in the
bottom three panels in Table 5. In these models, the treatment his-
tory variables for monotherapy, dummy variables documenting the
patient’s use of medications in the prior 6 months, and the number of
episodes initiated per year prior to the episode index data are again
left out of the “no history” models.
Leaving out the treatment history variables consistently favors
the atypical antipsychotics when compared to TAP for TTAD
across all episode types. The bias introduced by leaving out treat-
ment history variables is less clear, however, in the cost analyses.
In general, the inclusion of treatment history variables results in
larger estimated cost increases for the atypical antipsychotics rel-
ative to TAP in restart episodes. The opposite is true in switching
and augmentation episodes because including treatment history
improved the estimated cost impact of using an atypical antipsy-
chotic relative to TAP. What is particularly interesting is the fact
that those atypical antipsychotics with no TTAD benefit relative to
TAP (olanzapine, risperidone) have the best cost profile of all of the
atypical antipsychotics.
Discussion
Treatment history has a significant impact on the estimated com-
parative effectiveness of atypical antipsychotics relative to con-
ventional antipsychotics using retrospective data. The implica-
tions of ignoring treatment history are particularly evident in
comparative effectiveness as measured by TTAD. Specifically, the
es: patients with schizophrenia: all treatment episodes:
Cox proportional hazards models
(Hazard ratios vs. TAP)
ute hospital
mission w/i
1 year
Time to D/C
initial Rx
Time to
D/C all Rx
Time to
switch in
Rx
Time to
acute
hospital
admission
Pseudo
R20.0831
0.74† 1.58† 3.44† 0.85† 0.76†
.096 1.12† 1.97† 1.41† 1.03
0.74† 1.13‡ 1.05 0.85‡ 0.76†
0.99 1.10‡ 1.03 0.98 0.91
0.82† 1.11† 1.08* 0.92‡ 0.85†
1.03 1.21† 1.11‡ 1.07* 0.95
1.11 1.16† 0.93* 1.14† 1.07
1.10 0.87 0.76 0.97 1.03
1.065† 0.986* 0.957† 1.053† 1.087†tcom
dels
)
/
t
r
Ac
ad
6new antipsychotics appear to achieve longer TTAD if the estima-
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685V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 7 9 – 6 8 6tion models ignore treatment history. This bias becomes even
more pronounced when the analyses are restricted to patients
with breaks in therapy [washout periods]. Ignoring treatment his-
tory, however, makes the newer medications appear to be more
costly in these retrospective comparative effectiveness compari-
sons with the exception of restart episodes.
Full transparency requires that a study should document the
patient’s treatment history and then use these variables to control
for the effects of treatment history of comparative effectiveness.
This approach was used by Chen et al. [1,2] when comparing olan-
apine, risperidone and quetiapine to TAP using Medicaid data
rom California. A total of 219,504 episodes of antipsychotic ther-
py were included in the analysis. Their results indicate that treat-
ent history has a significant impact on TTAD and post-treat-
ent costs. Unlike the results reported here, however, the atypical
ntipsychotics were consistently associated with longer TTAD
han TAP for all episode types, ranging from 13 to 15 days for
estart episodes and 31 to 38 days for augmentation episodes. Dif-
erences across the atypical antipsychotics were small. The atyp-
cal antipsychotics were also associated with lower cost in restart
nd augmentation episodes, but not switching episodes.
The results reported here and in Chen et al. [1,2] should engen-
er concern on the part of clinicians, pharmacy and therapeutics
Table 5 – Sensitivity of comparative effectiveness results c
independent variables for treatment history [TAP as comp
Duration on in
Model with no drug
history variables
All episodes: N  21,570 R2  0.0282
Olanzapine 14.7
Risperidone 11.1*
Quetiapine 44.5†
Ziprasidone 60.5†
Aripiprazole 51.1†
Mood stabilizer 45.1†
Antidepressant 25.6†
Restart episodes: N  4,633 R2  0.0473
Olanzapine 46.7*
Risperidone 24.0*
Quetiapine 63.7†
Ziprasidone 44.0‡
Aripiprazole 62.0†
Mood stabilizer 53.6†
Antidepressant 22.4‡
Switching episodes: N  3,486 R2  0.0801
Olanzapine 1.0
Risperidone 28.7†
Quetiapine 38.2†
Ziprasidone 34.2*
Aripiprazole 18.1
Mood stabilizer 47.6†
Antidepressant 33.8†
Augmentation episodes: N  13,451 R2  0.0323
Olanzapine 17.2
Risperidone 20.0‡
Quetiapine 44.4†
Ziprasidone 79.3†
Aripiprazole 64.0†
Mood stabilizer 46.7†
Antidepressant 29.9†
AP, antipsychotic; TAP, typical antipsychotics.
* P  0.05; † P  0.0001; ‡ P  0.01.ommittees, HMOs, insurance companies, and government pro- arams about possible bias in retrospective database research that
s narrow in scope and/or fails to take into account patient treat-
ent history. This concern should extend beyond severe mental
isorders to include any disease state in which long-term drug
herapy is indicated but difficult to achieve. Hopefully, the stan-
ard of practice for observational research will move toward in-
luding the full range of treated patients and accounting for each
atient’s treatment history in their analyses.
Clinicians, pharmacy and therapeutic committees, health in-
urance companies, HMOs and government programs must be
ware of the potential for bias in comparative effectiveness re-
earch based on retrospective data. These studies typically con-
ider very restricted sub-samples of all observable patient treat-
ent episodes, focusing instead on patients with extended
eriods in which no relevant drugs are used. The potential for
ystematic bias is particularly troublesome in studies comparing
nly 2 to 3 antipsychotic drugs and requiring an extended washout
eriod on these study drugs while allowing the prior use of other
edications. For example, Rascati et al. [3] compared olanzapine
n 1906) and risperidone (n 979) using Texas Medicaid data for
atients with schizophrenia newly started on these products. Pa-
ients being treated with olanzapine were less likely to discon-
inue treatment during the first year (8.89% vs. 14.51%, P  0.0001)
aring antipsychotics to model specifications with/without
n drug].
AP Total costs ($/year)
el with drug
ory variables
Model with no drug
history variables
Model with drug
history variables
R2  0.0544 R2  0.2081 R2  0.2182
8.4 569 205
1.8 653 217
23.6† 4022† 3135‡
39.9† 3635* 3178*
30.8† 1982 1811
25.4† 4013† 2312*
5.7 1605* 343
R2  0.0812 R2  0.2124 R2  0.1934
9.5 610 289
2.3 1523 864
9.4 9620† 5524*
8.1 580 5174
4.8 2237 2427
34.1‡ 2593 3290
4.6 391 503
R2  0.0851 R2  0.2105 R2  0.2401
13.8 484 576
23.2 1643 2662
27.0 5179* 8039‡
0.8 4683 1764
18.3 2580 1515
8.8 5943† 656
20.9 2665 434
R2  0.0441 R2  0.2134 R2  0.2162
12.1 1630 359
0.9 274 585
22.7* 2451 1573
57.5† 4751* 3866
40.5† 2362 1471
25.8‡ 4128† 2888*
8.6 1851 820omp
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686 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 7 9 – 6 8 6days, P  0.0001) than risperidone patients. Gibson et al. [4] com-
pared episodes of drug therapy for Michigan Medicaid patients
with schizophrenia treated with olanzapine (n 458), risperidone
(n  481) or haloperidol (n  252). A 6-month washout period was
equired between episodes using the same drug (a restart episode)
nd a 30-day washout period was required for the other study
rugs (a delayed switching episode). Fifty-nine percent (59%) of
lanzapine patients were taking a concomitant non-study anti-
sychotic at the start of the episode (switching or augmentation
pisodes) compared with 39% of risperidone patients. Unadjusted
TAD data did favor olanzapine over risperidone (166 days vs. 128
ays) whereas compliance with haloperidol was significantly worse
elative to both olanzapine and risperidone. Finally, Yu, et al. [5] se-
ected adult patients with schizophrenia from the Pennsylvania
edicaid program. The study was limited to patients who initiated
ither olanzapine or quetiapine monotherapy after a 90-day washout
eriod on these drugs, although prescriptions using other antipsy-
hotics were allowed during this period. Propensity score methods
ere used to match patients and data on treatment history were
ncluded in the propensity model for the use of quetiapine. Olanzap-
ne patients were estimated to be less costly relative to quetiapine
atients primarily due to reduced hospitalization costs.
Limitations
Analyses based on paid claims data have a host of limitations that
must be considered in interpreting their results. First, clinical data
documenting potential differences in severity of illness and sen-
sitivity to side effects across alternative drugs are not available on
paid claims. For example, it may be the case that patients who
initiate augmentation episodes are more severely ill and thereby
motivated to maintain continuous therapy. Patients who use drug
therapy intermittently (restart episodes) may be less severely ill or
may experience more symptom-free periods during which they do
not consume high levels of health-care services.
Using the gap of 15 days to define discontinuation of drug ther-
apy can be debated. For restart episodes, substituting an alterna-
tive gap of 30 days would collapse sequential restart episodes sep-
arated by 16 to 30 days into a single episode and increase the
average duration of therapy. It is unclear whether or not this
change would favor one drug or class of drugs over another. Un-
fortunately, conducting sensitivity analyses of different definition
of gaps in treatment used to define episodes cannot be accom-
plished by simply toggling between different definitions. Each al-
ternative definition of the maximum gap allowed in defining dis-continuation of therapy would require that the entire data set be
reconstructed.
This analysis also dropped all first observed episodes due to
possible left-censoring of the data, which made it impossible to
document the treatment history of the episode. One could select
only those first observed episodes with 6 months to 1 year of pre-
treatment data with no antipsychotic drug use for separate anal-
yses. This sensitivity analysis was beyond the scope of this study,
which focused on the impact of missing treatment history on pa-
tient outcomes. Moreover, there are several studies already in the
literature that use this selection process to simplify the statistical
methods they apply in their studies.
Source of financial support: The data set used in this research
was developed as part of a research grant from Bristol-Myers
Squibb (BMS) to the University of Southern California, which re-
tains the unrestricted publication rights to all research findings.
R E F E R E N C E S
[1] Chen L, McCombs JS, Park JX. The impact of atypical antipsychotic
medications on the use of health care by patients with schizophrenia.
Value Health 2008;11:34–43.
[2] Chen L, McCombs JS, Park JX. Duration of antipsychotic drug therapy
in real world practice: a comparison with CATIE trial results. Value
Health 2008;11:487–96.
[3] Rascati KL, Johnsrud MT, Crismon ML, et al. Olanzapine versus
risperidone in the treatment of schizophrenia: a comparison of costs
among Texas Medicaid patients. Pharmacoeconomics 2003;21:683–97.
[4] Gibson PJ, Damler R, Jackson EA, et al. The impact of olanzapine,
risperidone, or haloperidol on the cost of schizophrenia care in a
Medicaid population. Value Health 2004;7:22–35.
[5] Yu AP, Ben-Hamadi R, et al. Comparing the treatment patterns of
patients with schizophrenia treated with olanzapine and quetiapine
in the Pennsylvania Medicaid population. Curr Med Res Opin 2009;25:
755–64.
[6] Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of
antipsychotic drugs in patients with chronic schizophrenia. N Engl
J Med 2005:353:1209–23.
[7] Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine,
quetiapine, risperidone and ziprasidone in patients with chronic
schizophrenia following discontinuation of a previous atypical
antipsychotic. Am J Psychiatry 2006:163:611–22.
[8] Marshall TS, McCombs JS, Stafkey-Mailey D. Impact of patient
selection criteria and treatment history on comparisons of alternative
therapies: a case study of atypical antipsychotics. Value Health 2009;
12:473–80.
[9] Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk
of rehospitalization among California Medicaid patients with
schizophrenia. Psychiatr Serv 2004;55:886–91.[10] White H. A heteroscedasticity-consistent matrix estimator and a
direct test for heteroscedasticity. Econometrica 1980;48:817–38.
